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calculations was not reported. From the 923 eligible patients, 551 (59.7%) of them were aged 70 years or older, 462 (50.1%) were male and 846 were white (92.8%).
A total of 480 (32.6%) patients did not meet study eligibility criteria or were unavailable for analysis. Patients excluded were those enrolled in the HMO for less than a year before diagnosis, and those with a known history of colon polyps, ulcerative colitis, Crohns disease or familial polyposis syndrome. Also excluded were those patients whose cancer was detected following screening endoscopy or an FOBT performed in their physician's office.
Study design
This was a retrospective cohort study performed in an HMO setting, serving a population of 450,000, with a 7-year follow-up period.
Analysis of effectiveness
The primary health outcomes used in the analysis were cancer stage at diagnosis, incidence, survival and mortality rates. In addition, a chronic disease score (CDS) was used for all patients and in both groups to compare non-cancer comorbidity at the time of diagnosis. The CDS is associated with physician-rated disease severity and patient-rated health status. It predicts subsequent mortality and hospitalisation rates.
Effectiveness results
The distribution of screen-versus symptom-detected cases among all persons with newly diagnosed CRC was equivalent over the years of observation (chi-squared p=0.32). For screen-detected cases, there was a mean of 2.06 months between the index FOBT test and the diagnosis of cancer. In relation to the stage at diagnosis, 51 (5.7%) were in situ, 257 (29.0%) were at Dukes A, 271 (30.6%) were at Dukes B, 181(20.4%) were at Dukes C, and 127 (14.3%) were at Dukes D. Screen-detected cancers had significantly earlier stages.
Thirteen patients in the screen-detected group and 133 patients in the symptom-detected group died during the 12-month follow-up period (chi-squared p<0.001). Non-cancer co-morbidity, as measured by the CDS, was not significantly different between the screen-and symptom-detected groups, (p=0.12).
Clinical conclusions
Screen-detected cases were more likely to be diagnosed with early-stage cancer.
Measure of benefits used in the economic analysis
No summary measure of benefit was used and the costs and effects were left disaggregated. The study was, therefore, classified as a cost-consequences analysis.
Direct costs
Discounting was not carried out because the costs were incurred during less than 2 years. The quantities and the costs were analysed separately and measured, but not reported. The data were obtained from a database consolidating resource use and costs. The database included the full cost of patient care services at the unit-of-service level. The cost per unit, (resulting from a step-down cost accounting system), reflected the actual costs of medical personnel and supplies to provide the service, as well as overhead costs such as administration, charting and automated information systems. Departments captured in the database included medical staff, nursing, pharmacy, laboratory, radiology, hospital inpatient and community health services. Data on the costs and quantities of resources used were collected from 1993 to 1999. All the costs were adjusted to 2002 dollars using the Consumer Price Index values for medical care/ser The costs were treated stochastically and a Kaplan Meier non-parametric test was used. The formulation accounted for censoring and months with zero costs. Confidence intervals (CIs) were derived to evaluate the statistical significance of differences between the groups. The costs for screen-and symptom-detected individuals were also stratified by age group and gender.
Indirect Costs
The indirect costs were not included.
Currency
US dollars ($).
Sensitivity analysis
Conservative (no stage shift with screening) and less conservative (stage shift occurring) scenarios were evaluated to predict the cost-savings over time with screening.
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
For all patients, at all stages, the diagnosis costs (i.e. the costs for the 3 months before diagnosis) were $2,959 lower for the screen-detected group than for the symptom-detected group, (p<0.005). The diagnosis costs were $7,302 (95% CI: 6,267 -8,338) and $10,261 (95% CI: 9,243 -11,279) for the screen-and symptom-detected groups, respectively.
Screen-detected cancers were significantly less expensive for both sexes, but the absolute difference was much greater for women ($3,657; p=0.005) than for men ($2,188; p=0.005). For women, the diagnosis costs were $7,486 (95% CI: 5,784 -9,187) for the screen-detected group compared with the $11,143 (95% CI: 9,395 -12,891) for the symptomdetected group. For men, the diagnosis costs were $7,149 (95% CI: 5,889 -8,408) for the screen-detected group compared with $9,337 (95% CI: 8,350 -10,324) for the symptom-detected group.
Stratifying by age showed that the cost of screen-and symptom-detected cancer were not significantly different for those younger than 65 years, but were approximately $3,000 less per person for those older than 65 years, (p<0.001).
Costs for the 12 months following diagnosis were significantly lower for the screen-detected group as a whole ($23,344 versus $29,384; p=0.001) . This was consistent with the stage distribution of persons with symptom-diagnosed cancer being more advanced than for individuals with screen-detected cancers.
For the 12 months following diagnosis, only persons diagnosed with Stage A cancers had significantly less expenses in the screen-detected arm ($17,267 versus $23,310; p=0.0013). When the costs were examined from the period 3 months before diagnosis to 12 months following diagnosis, the diagnosis costs were also significantly lower for persons diagnosed with Stage A cancer, with a consistent trend toward lower costs across all other stages at diagnosis. The costs of care for patients were significantly and substantially lower in the screen-detected group than in the symptom-detected group over the observed period (3 months before diagnosis to 12 months following diagnosis, $24,636 versus $31,128; p=0.0005).
The authors stated that under a conservative assumption (that the stage distribution for the symptom-detected group would not change under screening), the total savings to the organisation achieved by screening over the 7 years of the study would have been $1,738,075 for the 3-month period immediately before diagnosis, and $2,978,828 for the entire 15-month pre-diagnosis/post-diagnosis period. On the contrary, with a less conservative assumption (that screening would result in a stage shift to the observed stage distribution from screening, as well as savings from eliminating symptom-detected cancers), the savings for the 15-month period would total $4,440,528. presented, only the costs attributable to diagnosis were examined. The costs associated with screening a defined population were not considered, for example, the costs of administering the tests and the costs associated with diagnostic evaluation of false-positive findings. This might have affected the findings, overestimating the savings achieved through screening.
Implications of the study
There is evidence that screening is usually underused. Nevertheless, it is possible that health plans can achieve substantial savings in diagnosis and treatment costs over what would have been spent in the absence of screening. Diagnosis costs have not been considered before in cost-effectiveness studies of CRC screening, and the savings achieved could be weighted against the costs of a screening programme. For this reason, in addition to their potential value for decision-makers in health plans who are considering funding screening programmes, these data may be useful for decision modellers who have to build or refine cost-effectiveness analyses of CRC screening modalities, since they were derived from a naturalistic setting. 
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